Safety and clinical implications of concurrent biopsy of neuroendocrine liver metastases at the time of liver-directed therapy
Endocrine Abstracts · 04.03.2026
DOI: 10.1530/endoabs.116.c13 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Abstracts, online erschienen am 04.03.2026. Verfasst von MBChB und 15 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
MBChB, Thuemmler,, B. R. J., Ackerman,, P. D., MD, Hunt,, P. S., Nadolski,, M. G., Metz,, M. D. C., Weinfurtner,, M. K., Li,, M. W., MD, Yang,, P. Z., Soulen,, M. M. C., MD, Gade, P. T., MD, & DePietro,, D. M. (2026). Safety and clinical implications of concurrent biopsy of neuroendocrine liver metastases at the time of liver-directed therapy. Endocrine Abstracts. https://doi.org/10.1530/endoabs.116.c13
Vancouver
MBChB, Thuemmler, BRJ, Ackerman, PD, MD, Hunt, PS, Nadolski, MG, et al. Safety and clinical implications of concurrent biopsy of neuroendocrine liver metastases at the time of liver-directed therapy. Endocrine Abstracts. 2026. doi:10.1530/endoabs.116.c13
BibTeX
@article{MBChB2026,
author = {MBChB and Thuemmler,, BSc Rosa J. and Ackerman,, PhD Daniel and MD and Hunt,, PhD Stephen and Nadolski,, MD Gregory and Metz,, MD David C. and Weinfurtner,, MD Kelley and Li,, MS Wuyan and MD and Yang,, PhD Zhaohai and Soulen,, MD Michael C. and MD and Gade, PhD Terence and MD and DePietro,, Daniel M},
title = {Safety and clinical implications of concurrent biopsy of neuroendocrine liver metastases at the time of liver-directed therapy},
journal = {Endocrine Abstracts},
year = {2026},
doi = {10.1530/endoabs.116.c13}
}
EUVIMED